Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04124406 · ClinicalTrials.gov registry record
Voyage: Real-World Impact of the Multi-target Stool DNA Test on CRC Screening and Mortality
A clinical trial of Colon Cancer, sponsored by Exact Sciences Corporation.
- Active
- Registry status
- 150,000
- Enrollment target
- 1
- Study location
NCT04124406: Active study of Colon Cancer, sponsored by Exact Sciences Corporation.
NCT04124406 is a study of Colon Cancer that is active but no longer recruiting, run by Exact Sciences Corporation. The registered enrollment target is 150,000 participants, above the 2,910-participant average among 97 other Colon Cancer trials with a reported enrollment target (5055% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04124406, a study of Colon Cancer, is active but no longer recruiting, sponsored by Exact Sciences Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- 150,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to gather information about the long term health of people who have been prescribed the Cologuard test, which is used for colorectal cancer (CRC) screening.
Primary Outcome
Enrollment of 150,000 subjects
Conditions Studied
Interventions
- DEVICE Cologuard
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150,000 participants |
| Start Date | 2019-10-18 |
| Est. Completion | 2025-12 |
What the registry record for NCT04124406 still lists
NCT04124406 is an observational study that tracks outcomes without assigning an intervention. Its 150,000 participants enrollment target places it among the larger protocols in the corpus, above the 2,910-participant average among 97 other Colon Cancer trials with a reported enrollment target (5055% higher).
The record links to 1 condition, with Colon Cancer appearing as the primary indexed condition, and to 1 intervention - of which Cologuard is the first listed.
NCT04124406 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT04124406 about?
NCT04124406 is a clinical study titled "Voyage: Real-World Impact of the Multi-target Stool DNA Test on CRC Screening and Mortality". The purpose of this study is to gather information about the long term health of people who have been prescribed the Cologuard test, which is used for colorectal cancer (CRC) screening.
What is the current status of trial NCT04124406?
This trial is currently active not recruiting. The enrollment target is 150,000 participants. The study started on 2019-10-18. Estimated completion is 2025-12.
What conditions does trial NCT04124406 study?
This clinical trial studies the following conditions: Colon Cancer.
What interventions are being tested in trial NCT04124406?
The interventions under investigation include: Cologuard (DEVICE).
Who is sponsoring clinical trial NCT04124406?
This trial is sponsored by Exact Sciences Corporation, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04124406 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colon Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04124406's enrollment target sits among peer trials
150,000 2nd of 97 the highest of 97 other Colon Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colon Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
RECRUITING
-
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
RECRUITING · Phase 1
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
-
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06232551 · 152,000 participants · NA
Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
- NCT06917339 · 156,000 participants
Retrospective Analyses of TrakStar Database
- NCT05994482 · 130,000 participants
Surveillance Colonoscopy in Older Adults: The SurvOlderAdults Study
- NCT02693509 · 128,026 participants
Get With The Guidelines-Heart Failure Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI